Family Medicine Doctors in Santa Claus, IN Accepting Medicare
2 Family Medicine doctors found. Showing 1 - 2
 Dr. Melinda J Gruber, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 92 W Christmas Blvd, Santa Claus, Santa Claus, IN 47579 Phone: 812-937-4120 Fax: 812-937-7074 |
Erin Marchand, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 92 W Christmas Blvd, Santa Claus, IN 47579 Phone: 812-937-4120 |
News Archive
Coordinated, two-part approach could help reduce hospital-acquired infections
By coordinating with state health departments and communicating with each other about patients with C. difficile and antibiotic-resistant infections, hospitals, long-term acute-care facilities and nursing homes could reduce the number of such hospital-acquired infections (HAIs) by an estimated 619,000 cases in the next five years, a new Centers for Disease Control 9 (CDC)-led report has found.
New NPO formed to accelerate development of therapies for Shankopathies
Parents of children affected by Phelan-McDermid syndrome (PMS) announce the formation of CureSHANK, a nonprofit organization on a mission to accelerate drug development in PMS and other diseases related to the SHANK genes for which there are currently no FDA approved treatments.
Lawmaker questions regulators about preventive-care provisions in health law
Sen. John Ensign (R-Nev.) has asked federal regulators to make sure new rules banning cost-sharing for preventive care don't inadvertently preclude employers from rewarding cost-effective care.
Study finds mitochondrial DNA damage in Veterans with Gulf War illness
Researchers say they have found the "first direct biological evidence" of damage in veterans with Gulf War illness to DNA within cellular structures that produce energy in the body.
Novartis' Gilenya uptake to increase
A study published this week by ITG revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.
› Verified 9 days ago